Overview Cabozantinib in Advanced Salivary Gland Cancer Patients Status: Terminated Trial end date: 2019-11-06 Target enrollment: Participant gender: Summary Phase 2 clinical trial on the efficacy of cabozantinib in locally advanced, recurrent and/or metastatic salivary gland cancer patients. Phase: Phase 2 Details Lead Sponsor: Radboud UniversityCollaborator: Ipsen